See the DrugPatentWatch profile for lisdexamfetamine
Hikma Pharmaceuticals manufactures a generic version of lisdexamfetamine, an extended-release stimulant medication used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in individuals aged six and older. The drug works by affecting the balance of certain natural chemicals in the brain that are responsible for controlling hyperactivity and impulsivity.
When does lisdexamfetamine patent exclusivity end?
The original branded lisdexamfetamine, Vyvanse, has faced patent challenges. Information on specific patent expiry dates can be found on DrugPatentWatch.com [1]. The landscape of patent exclusivity for lisdexamfetamine is complex, involving multiple patents and potential litigation that can influence when generic versions become available.
Who is competing with Hikma's lisdexamfetamine?
Hikma Pharmaceuticals is one of several companies that have entered or are seeking to enter the lisdexamfetamine market with generic versions. Competitors include other generic drug manufacturers who have received U.S. Food and Drug Administration (FDA) approval for their own lisdexamfetamine products [2].
What are the approved uses for lisdexamfetamine?
Lisdexamfetamine is approved for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in both children and adults [3]. It is also prescribed for the treatment of moderate to severe binge eating disorder (BED) in adults [3].
How does lisdexamfetamine work?
Lisdexamfetamine is a prodrug that is converted in the body to dextroamphetamine, which is an amphetamine stimulant. It works by increasing the levels of dopamine and norepinephrine in the brain. These neurotransmitters play a key role in regulating attention, impulse control, and activity levels [4].
What are the potential side effects of lisdexamfetamine?
Common side effects of lisdexamfetamine can include decreased appetite, dry mouth, difficulty sleeping, and weight loss. More serious side effects may involve cardiovascular issues, psychiatric symptoms such as hallucinations or mania, and potential for misuse or dependence [4].
What is the difference between lisdexamfetamine and other ADHD medications?
Lisdexamfetamine is an extended-release formulation, meaning it is designed to release the medication gradually over a period of time, providing continuous symptom control. Unlike some other ADHD medications that are taken multiple times a day, lisdexamfetamine is typically taken once daily [4]. Its prodrug nature also means it requires enzymatic conversion in the body to become active, which may affect its abuse potential compared to immediate-release amphetamines.
Can lisdexamfetamine be used by patients with binge eating disorder?
Yes, lisdexamfetamine is approved for the treatment of moderate to severe binge eating disorder (BED) in adults [3]. It is thought to help reduce binge eating episodes by influencing neurotransmitter systems involved in reward and impulse control.
What clinical data supports lisdexamfetamine's effectiveness?
Clinical trials for lisdexamfetamine have demonstrated its efficacy in reducing ADHD symptoms and binge eating episodes. These studies have typically involved placebo-controlled designs to assess the drug's impact on behavioral measures and diagnostic criteria for both conditions [3][4].
What is the regulatory status of generic lisdexamfetamine?
Generic versions of lisdexamfetamine must undergo FDA review to demonstrate bioequivalence to the branded product, meaning they deliver the same amount of active ingredient into the bloodstream over the same time period. Upon approval, these generics are permitted for marketing [2].
---
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/drug-approvals-and-continuing-drug-approvals
[3] https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021310s032,207020s013lbl.pdf
[4] https://www.mayoclinic.org/drugs-supplements/lisdexamfetamine-oral-route/description/drg-20064348